Valeant's $344M Obagi Buy Rips Off Investors, Suit Says
A proposed shareholder class action filed Friday against Obagi Medical Products Inc. is seeking to block the $344 million buyout by Canadian drugmaker Valeant Pharmaceuticals International Inc., claiming the deal shortchanges...To view the full article, register now.
Already a subscriber? Click here to view full article